Symbols

CDNA

CareDx·NASDAQ

--(--)

Market Open: --

--(--)

Pre-Market: --

Signals Analysis

Bullish signal 6

Bearish signal 0

Consensus Rating "Strong Buy"

Ample Liquidity

High Gross Profit Margin

High Cash/net Profit Ratio

Revenue Beats Expectation

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About CDNA

Caredx, Inc.

A leading precision medicine solutions company that focused on developing healthcare solutions for transplant patients and caregivers

Industry

Healthcare Equipment and Supplies

Established Date

12/21/1998

Listing Date

07/17/2014

Exchange

NASDAQ Stock Exchange

Full-time Employees

644

Fiscal Year Ends

12-31

Website

www.caredx.com

Security Type

Common stock

Office address

8000 Marina Boulevard, Brisbane, California 94005

Business

Introduction

CareDx, Inc., was incorporated in Delaware on December 21, 1998. The company is a commercial stage company that develops decision markets and provides heart transplants to patients to help clinicians diagnose, monitor solutions and personalize treatments. CareDx's first commercialized test protocol, AlloMap Molecular Test Heart Transplant, or AlloMap Blood-Based Test, is used to monitor acute cellular rejection after heart transplantation.

Earnings Call

Q2/2025

Estimate EPS0.12

Actual EPS0.1

Estimate Revenue90.56M

Actual Revenue86.68M

CareDx's Q2 2025 Earnings: Unpacking Contradictions in EPIC Launch, Legal Settlements, and Volume Growth

Aug 11,2025 10:55·
Earnings Decrypt

Company Financials

EPS

CDNA has released its 2025 Q3 earnings. EPS was reported at 0.28, versus the expected 0.14, beating expectations. The chart below visualizes how CDNA has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

CDNA has released its 2025 Q3 earnings report, with revenue of 100.06M, reflecting a YoY change of 20.72%, and net profit of 1.68M, showing a YoY change of 115.75%. The Sankey diagram below clearly presents CDNA's revenue sources and cost distribution.